Puerarin pharmaceutical composition with brain injury protection effect

[0024] Embodiment 1: Determination of brain protection activity

[0025] 1. Experimental materials

[0026] Healthy male SD rats (body weight 220±20g) were fed in an SPF-grade animal feeding environment, and were adaptively fed for 1 week. The rats were free to eat and drink. Fasting 12h before the operation, free to drink water.

[0027] The purity of puerarin and purple salvia terpene is not less than 98%, and 0.1% DMSO is used in the solvent to aid dissolution.

[0028] 2. Experimental method

[0029] 1. Grouping, modeling and administration

[0030] Healthy male SD rats (body weight 220±20g) were randomly divided into sham operation group, model group, puerarin group, red salvia terpene group, red salvia terpene + puerarin group, 8 rats in each group. Model group, puerarin group, purple salvia terpene group, purple salvia terpene + puerarin group were used to establish cerebral ischemia-reperfusion injury model by suture embolization: the rats were anesthetized and fixed

[0039] Embodiment 2: BBB transmittance measurement

[0040] Prepare blood-brain barrier (BBB) ​​in vitro experimental model according to the literature method (Effect of borneol on puerarin passing through simulated blood-brain barrier in vitro, Chinese Herbal Medicine Volume 48, No. 16, August 2017), and determine the passage of drugs through the BBB in vitro model. permeability.

[0041] 1. Experimental materials

[0042] Mouse brain microvascular endothelial cells (bEnd.3) were purchased from Shanghai Yaji Biotechnology Co., Ltd.

[0043] The purity of puerarin and purple salvia terpene is not less than 98%, and 0.1% DMSO is used in the solvent to aid dissolution.

[0044] DMEM high-glucose medium, FBS and penicillin and streptomycin were purchased from Gibco.

[0045] 12-well Transwell cell culture plate (0.4 μm) was purchased from Corning Company.

[0046] 2. Experimental method

[0047] 1. In vitro culture of endothelial cells bEnd.3

[0048] Endothelial cells bEnd.3

[0062] Embodiment 3: pharmaceutical composition

[0063] A pharmaceutical composition is composed of puerarin B and purple salvia terpene, and the composition can be made into a pharmaceutically acceptable dosage form with pharmaceutically acceptable auxiliary materials for preparing brain-protecting pharmaceutical preparations.